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COMPOSITIONS AND METHODS FOR 
TREATING RETINAL DEGRADATION 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
2 
to other embodiments of the presently-disclosed subject 
matter, whether listed in this summary or not. To avoid 
excessive repetition, this summary does not list or suggest 
all possible combinations of features. 
The present disclosure provides, in certain embodiments, 
a method for treating retinal damage and/or degradation, 
comprising administering an effective amount of a compo-
sition to a subject in need thereof, wherein the composition 
10 comprises a reverse transcriptase inhibitor, such as a nucleo-
side reverse transcriptase inhibitor (NRTI), selected from: (i) 
a compound having the structure of 
This application is a continuation of U.S. patent applica-
tion Ser. No. 15/142,087, filed Apr. 29, 2016, now U.S. Pat. 
No. 10,300,057, issued May 28, 2019, which is a continu-
ation of U.S. patent application Ser. No. 14/450,000, filed 
Aug. 1, 2014, now U.S. Pat. No. 9,326,983, issued May 3, 
2016, which claims the benefit of U.S. Provisional Patent 
Application Ser. No. 61/861,290, filed Aug. 1, 2013, and 
U.S. Provisional Patent Application Ser. No. 61/987,612, 
filed May 2, 2014, the entire disclosures of which are 15 
incorporated herein by this reference. 
TECHNICAL FIELD 
The presently-disclosed subject matter relates to compo- 20 
sitions for treating retinal damage and/or degradation. More 
specifically, this disclosure relates to methods for treating 
degradation of the retinal pigment epithelium by adminis-
tering compositions comprising a nucleoside and/or a 
nucleoside reverse transcriptase inhibitor (NRTI). 25 
BACKGROUND 
30 or a pharmaceutically acceptable salt thereof; 
(ii) a compound having the structure of 
Geographic atrophy, an advanced form of age-related 
macular degeneration that causes blindness in millions of 
people worldwide and for which there is no approved 
treatment, results from death of retinal pigmented epithe-
lium (RPE) cells. For example, expression of DICER, an 
enzyme involved in microRNA (miRNA) biogenesis, is 
reduced in the RPE of human eyes with geographic atrophy, 35 
and that conditional ablation of Dicer! induces RPE degen-
eration in mice. Surprisingly, ablation of seven other 
enzymes responsible for miRNA biogenesis or function does 
not induce such pathology. Instead, knockdown ofDICERl 
leads to accumulation of Alu repeat RNA in human RPE 40 
cells and of Bl and B2 (Alu-like elements) repeat RNAs in 
the RPE of mice. Alu RNA is dramatically increased in the 
RPE of human eyes with geographic atrophy, and introduc-
tion of this pathological RNA induces death of human RPE 
cells and RPE degeneration in mice. 45 
Age-related macular degeneration (AMD), which is as 
prevalent as cancer in industrialized countries, is a leading 
cause of blindness worldwide. In contrast to the neovascular 
form of AMD, for which many approved treatments exist, 
the far more common atrophic form of AMD remains poorly 50 
understood and without effective clinical intervention. 
Extensive atrophy of the retinal pigment epithelium leads to 
severe vision loss and is termed geographic atrophy. 
Hence, there remains a need for compositions and meth-
ods for treating retinal degradation, and particularly RPE 55 
degradation. 
BRIEF SUMMARY 
This summary describes several embodiments of the 60 
presently-disclosed subject matter, and in many cases lists 
variations and permutations of these embodiments. This 
s=ary is merely exemplary of the numerous and varied 
embodiments. Mention of one or more representative fea-
tures of a given embodiment is likewise exemplary. Such an 65 
embodiment can typically exist with or without the 
feature(s) mentioned; likewise, those features can be applied 
or a pharmaceutically acceptable salt thereof; (iii) stavudine 
(d4T); (iv) lamivudine (3TC); (v) cordycepin; (vi) azido-
thymidine (AZT); (vii) abacavir (ABC); and/or (viii) a 
combination thereof. 
Moreover, the methods of the present disclosure may 
further comprise the steps of (i) inhibiting inflanimasome 
activation by Alu RNA; (ii) reducing ATP-induced perme-
ability of a cell; (iii) reducing an amount of mitochondria 
(reactive oxygen species in a cell; and/or (iv) inhibiting 
activation of at least one inflammasome in a subject's eye. 
Additionally, the cell(s) of the methods of the present 
disclosure may be chosen, for example, from a retinal 
pigmented epithelium cell, a retinal photoreceptor cell, a 
choroidal cell, and a combination thereof. And an inflam-
masome of the present disclosure may be, for example, an 
NLRP3 inflammasome, an IL-1 beta inflammasome, or a 
combination thereof. 
US 10,864,212 B2 
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Furthermore, in some embodiments, the present disclo-
sure provides a compound having the structure: 
or a pharmaceutically acceptable salt thereof; 
or a compound having the structure 
or a pharmaceutically acceptable sale thereof. 
The present disclosure also provides a pharmaceutical 
composition comprising at least one of the compounds 
provided in the present disclosure, together with a pharma-
ceutically acceptable carrier. And further embodiments of 
the present disclosure include a method for synthesizing at 
least one compound provided in the present disclosure. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 displays a top row of ocular fundus photographs of 
mice receiving control PBS, or Alu RNA treatment, with or 
without increasing amounts of d4T (left to right); and RPE 
flat mounts, stained for intercellular junctions (ZO-1) in red 
that are disrupted upon Alu RNA administration but that are 
restored to healthy RPE morphology/intercellular junctions 
at highest dose of d4T. 
4 
compared to control antisense oligonucleotides (Ctr as) (lane 
1 (leftmost)), and co-administration of d4T (lanes 2 and 4) 
does not reduce Alu RNA levels. u6 (bottom row) is shown 
as a loading control for nuclear fraction. 
FIG. 4 provides another example of the results of North-
ern blotting using an Alu-specific probe. As presented in 
FIG. 4, co-administration of d4T does not change Alu RNA 
levels at 1, 4, or 24 hours after transfection in the nuclear 
fraction of human RPE cells transfected with Alu RNA, with 
10 or without d4T, as detected by Northern blotting using an 
Alu-specific probe. u6 (bottom row) is shown as loading 
control for nuclear fraction in FIG. 4. 
FIG. 5 provides the results of a Western blot showing that 
Alu RNA causes Caspase-1 maturation in primary human 
15 RPE cells at 24 hours after Alu administration (top, middle 
lane, lower band), which is blocked by co-treatment with 
d4T (100 uM; rightmost lane). The bottom row is a vinculin 
loading control. 
FIG. 6 is a Western blot showing that Alu RNA causes 
20 Caspase-1 maturation in primary human RPE cells at 24 
hours after Alu administration (top, middle lane, lower 
band), which is blocked with co-treatment with 3 TC (20-100 
uM; rightmost lane), wherein the lowermost band is the 
25 
loading control, vinculin. 
FIG. 7 is a Western blot showing that Alu RNA causes 
Caspase-1 maturation in primary human RPE cells at 24 
hours after Alu administration (top, middle lane, lower 
band), which is blocked with co-treatment with azidothy-
midine (AZT), cordycepin, and abacavir (ABC) (50-100 
30 uM; lanes 3-8 from left). The loading control vinculin is 
shown on the bottom. 
FIG. 8 provides a gel showing that primary human RPE 
cells treated with LPS/ATP, a classic inflammasome activa-
tor, exhibit increased Casp-1 activation, and phosphory-
35 lation of IRAK4, which is also a marker of inflanimasome 
signaling via the cell surface receptor adaptor protein 
MyD88. Moreover, as shown in FIG. 8, d4T (25/100 uM) 
blocks Casp-1 activation and IRAK4 phosphorylation 
induced by LPS/ ATP. Vinculin was used as the loading 
40 control in the gel of FIG. 8. Additionally, as shown, LPS and 
ATP activate the NLRP3 inflammasome only in combina-
tion. 
FIG. 9 provides the results of Western blotting, wherein 
d4T, 3TC, and cordycepin (at 100 uM), all di-deoxy nucleo-
45 side reverse transcriptase inhibitors, are shown to inhibit 
Caspase-1 activation (active p20 band, top) and IL-18 matu-
ration (bottom) induced by LPS/ATP. To produce FIG. 9, 
cell culture supernatants were collected after (i) no treat-
ment, (ii) LPS treatment, or (iii) LPS/ATP treatment of 
50 mouse bone marrow-derived macrophages and run on West-
ern blotting probing with antibodies for Caspase-1 and 
IL-18. 
FIG. 10 provides the result of a Western blot showing that 
d4T (100, 250 uM) inhibits IL-1 beta maturation (top, 18 and 
55 22 kDa forms) and Caspase-1 activation (active p20 band, 
bottom) induced by nigericin. To produce FIG. 10, cell 
culture supernatants were collected after (i) no treatment, (ii) 
LPS treatment, or (iii) LPS/nigericin treatment of mouse 
FIG. 2 provides a bar graph showing that human (HeLa) 
cells treated with an enforced expression plasmid for Alu 
RNA (pAluA) for denoted amounts of time exhibited pro-
foundly reduced viability compared to a null plasmid 
(pUC19), as monitored by MTS proliferation assay and that 60 
d4T co-administration prevented cell death induced by Alu 
bone marrow-derived macrophages and run on Western 
blotting probing with antibodies for IL-1 beta and Caspase-
1. 
overexpression. 
FIG. 3 shows the results of Northern blotting using an 
Alu-specific probe. As presented in FIG. 3, primary human 
RPE cells treated with antisense oligonucleotides targeting 65 
DICER! (Der as) (lane 3 (third lane from left)) show 
increased Alu RNA levels in the nuclear compartment 
FIG. 11 shows a bar graph illustrating that d4T does not 
inhibit IL-1 beta secretion from PMA-differentiated THP-1 
monocytes induced by monosodium urate (MSU). FIG. 11 
was created after human THP-1 monocytes were differen-
tiated into macrophages with PMA, and, as shown in FIG. 
11, treatment with MSU, a known inflammasome activator, 
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increased IL-1 beta secretion compared to non-treated cells, 
whereas d4T co-administration at a range of doses (25-1000 
uM) did not significantly affect IL-1 beta secretion. 
FIG. 12 is a bar graph, which shows that d4T and other 
nucleoside reverse transcriptase inhibitors do not inhibit 5 
IL-1 beta secretion from PMA-differentiated THP-1 mono-
6 
PRO, and fluorescence (in relative fluorescence units) at 
485/515 nm was measured at t=30 minutes. 
FIG. 20 provides a chemical structure of methoxy-d4T 
(me-d4T). More specifically, as shown in FIG. 20, a single 
substitution of the ribose 5' hydroxyl group of d4T with a 
methoxy group (circled) has been designed to prevent d4T 
phosphorylation cytes induced by MSU. Human THP-1 monocytes were 
differentiated into macrophages with PMA. Their treatment 
with MSU increased IL-1 beta secretion compared to non-
treated cells, as shown in FIG. 12, while co-administration 
of d4T, 3TC, or cordycepin (all are di-deoxy nucleotide 
analogs) at a range of doses (25-1000 uM) did not signifi-
cantly affect IL-1 beta secretion. 
FIG. 21 is a Western blot of Caspase-1 activation (p20 
subunit) in primary human RPE cells transfected with Alu 
10 RNA±me-d4T. 
FIG. 13 is a graph, which provides that d4T reduces 
15 
NLRP3 priming induced by Alu RNA. Indeed, as shown in 
FIG. 13, Alu RNA transfection increases NLRP3 mRNA 
levels in primary human RPE cells at 16 hours, an event 
termed "priming" (Y-axis) compared to mock (transfection 
reagent alone). This effect is blunted by co-administration of 20 
d4T (100 uM) and normalized to 18S RNA control. 
FIG. 14 illustrates, in graph format, that Alu RNA trans-
fection increases IL-1 beta mRNA levels in primary human 
RPE cells at 24 hours, an event termed "priming", (Y-axis) 
compared to mock (transfection reagent alone). This effect is 25 
blunted by co-administration of d4T (100 uM) and normal-
ized to 1 SS RNA control. 
FIG. 22 shows cells, wherein unmodified d4T, but not 
me-d4 T, blocks replication of a GFP-expressing lentivirus in 
HeLa cells. 
FIG. 23 provides a graph illustrating that unmodified d4T, 
but not me-d4T, reduces mtDNA levels (normalized to 
chromosomal DNA exon-intron junction sequence) in pri-
mary mouse RPE cells as determined by real-time quanti-
tative PCR. n=4, *p<0.05 by Student's t-test. 
FIG. 24 provides flat mounts stained for zonula 
occludens-1 (ZO-1; red), bottom row. Degeneration outlined 
by blue arrowheads. Representative images of n=4 (B, C, E) 
shown. Scale bars, (C): 200 µm; (E): 20 µm 
FIG. 25 provides a schematic overview of me-d4T syn-
thesis. 
FIG. 26 is an HPLC chromatogram of me-d4T (peak #6) 
final product, >97% purity. 
FIG. 27 is a lH NMR spectroscopy of me-d4T final 
product, wherein the chemical shifts are consistent with the 
structure of me-d4T. 
FIG. 28 provides the results of liquid chromatography/ 
mass spectrometry of me-d4T final product, m/z ratio con-
sistent with the structure of me-d4T. 
FIG. 29 provides the methoxy variant of a nucleoside 
analog. The chemical structure of 3TC (2'3' dideoxycyti-
dine) is shown, wherein the methoxy variation (O-methyl 
group) of nucleoside analog is circled. 
FIG. 15 shows that d4T reduces mitochondrial ROS 
caused by Alu expression. Indeed, FIG. 15 demonstrates that 
enforced expression of Alu (pAluA) causes increased mito- 30 
chondrial reactive oxygen species (mtROS), as detected by 
MitoSox assay. In order to produce FIG. 15, primary human 
RPE cells were incubated with Alu expressing plasmid or 
control plasmid (pUC19) with or without d4T. After 15 
hours cells were co-stained for mtROS (red) and for cell 35 
count, nuclei (blue; Hoechst DNA stain). Cells in the pAluA 
group exhibited greater mtROS staining (red) compared to 
pUC19 control, an effect that is reduced in pAluA+d4T 
treated cells. 
FIG. 16 provides a graph showing that d4T does not 
inhibit ATP release induced by Alu RNA. Moreover, primary 
human RPE cells treated with Alu RNA, for the times 
indicated in FIG. 16, release ATP. Cell culture supernatant 
was collected from mock or Alu RNA treated cells, with or 
without d4 T, and ATP was detected using an ATP-dependent 45 
luciferase assay. Notably, d4T did not affect ATP release. 
FIG. 30 provides the methoxy variant of a nucleoside 
analog. The chemical structure of AZT (3'-azido-2',3'-dide-
oxythymidine) is shown, wherein the methoxy variation 
40 (O-methyl group) of nucleoside analog is circled. 
FIG. 31 provides the methoxy variant of a nucleoside 
analog. The chemical structure of ABC (cyclopropylami-
nopurinylcyclopentene) is shown, wherein the methoxy 
variation (O-methyl group) of nucleoside analog is circled. 
FIG. 32 shows a cell permeant variant of d4T (IC-d4T), 
where "n" group is equal to 11. Derivatives include cell 
permeant variants of3TC, AZT, ABC, where the nucleobase 
group ( circled) may be replaced, in various embodiments, by 
3TC, AZT, ABC, or methoxy-variants of d4T, 3TC, AZT, 
FIG. 17 shows that d4T reduces ATP-induced cell per-
meability to Yo-Prol (P2X7 receptor assay). Indeed, d4T 
dose-dependently reduced Yo-Pro entry induced by ATP, 
determined by an area-scan fluorescent measurement in a 96 
well microplate reader. FIG. 17 provides the results of the 
fluorescence measurement in relative fluorescence units 
(RFU, y-axis). 
50 ABC (FIG. 29-31), or derivatives thereof. 
FIG. 33 provides the structure of an exemplary NRTI 
according to the present disclosure. 
FIG. 34 is a Western blot of Caspase-1 activation (p20 
subunit) and IRAK4 phosphorylation in primary human 
55 RPE cells transfected with Alu RNA±d4T. 
FIG. 18 illustrates, in graph format, that d4T reduces 
extracellular potassium levels, which increase after Alu 
RNA transfection. Indeed, cell culture potassium levels 
increase in primary human RPE cells treated with Alu RNA 
for 6 hours, an effect that is reduced by d4T co-administra-
tion. Potassium levels were determined in cell culture super-
natants spectrophotometrically using a potassium-dependent 60 
pyruvate kinase assay. 
FIG. 19 shows that d4T blocks bzATP-induced cell per-
meability to Yo-Prol (P2X7 receptor assay). To prepare FIG. 
19, d4T blocked YO-PRO-1 iodide entry in HEK293 cells 
stably expressing the human P2X7 receptor stimulated with 65 
the P2X7-selective agonist bzATP. Cells were pre-incubated 
with d4T for 30 minutes prior to addition of bzATP/YO-
FIG. 35 is a Western blot of Caspase-1 activation in 
human RPE cells transfected with Alu RNA±NRTis (3TC, 
AZT, ABC). 
FIG. 36 includes fundus photographs: top row; flat 
mounts stained for zonula occludens-1 (ZO-1; red), bottom 
row. bars, 50 µm. 
FIG. 37 provides fundus photographs: top row; flat 
mounts stained for zonula occludens-1 (ZO-1; red), bottom 
row. Scale bars, 50 µm. 
FIG. 38 illustrates that NRTis block LPS/ATP-induced 
inflammasome activation. Specifically, FIG. 38 shows a gel 
indicating that d4T blocked Caspase-1. 
US 10,864,212 B2 
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FIG. 39 also illustrates that NRTis block LPS/ATP-
induced inflammasome activation, showing specifically a 
gel indicating that d4T blocked IL-1 beta. 
8 
skill in the art after a study of the information provided in 
this document. The information provided in this document, 
and particularly the specific details of the described exem-
FIG. 40 presents chromatograms showing that Raji TK+ 
cells, but not Raji TK- cells, phosphorylate AZT to AZT- 5 
triphosphate (AZT-TP) as determined by liquid chromatog-
raphy-mass spectrometry (LC-MS). 
plary embodiments, is provided primarily for clearness of 
understanding and no unnecessary limitations are to be 
understood therefrom. In case of conflict, the specification of 
this document, including definitions, will control. 
FIG. 41 shows that AZT blocks IL-1 beta activation by 
LPS/ATP in both Raji TK- and TK+ cells, as determined by 
Western blot of cell lysates. 
FIG. 42 is a bar graph illustrating that d4T does not block 
Alu-induced ATP release from primary human RPE cells 
(n=4). 
The presently-disclosed subject matter is illustrated by 
specific but non-limiting examples throughout this descrip-
10 tion. The examples may include compilations of data that are 
representative of data gathered at various times during the 
course of development and experimentation related to the 
present invention(s). Each example is provided by way of 
FIG. 43 provides a graph of P2X7-mediated YO-PRO-1 
dye uptake (fluorescence) induced by bzATP (100 µM) in 15 
HEK293 cells stably expressing the human P2X7 receptor 
was inhibited by d4T and A438079 (64 µM for both drugs). 
Fluorescence values are baseline subtracted from cells with-
out bzATP treatment. * bzATP vs. d4T; # bzATP vs. 
A438079, p<0.05 by Student-Newman Keuls post-hoc test 20 
(n=12). 
explanation of the present disclosure and is not a limitation 
thereon. In fact, it will be apparent to those skilled in the art 
that various modifications and variations can be made to the 
teachings of the present disclosure without departing from 
the scope of the disclosure. For instance, features illustrated 
or described as part of one embodiment can be used with 
another embodiment to yield a still further embodiment. 
All references to singular characteristics or limitations of 
the present disclosure shall include the corresponding plural 
characteristic(s) or limitation(s) and vice versa, unless oth-
erwise specified or clearly implied to the contrary by the 
FIG. 44 is a Western blot of Caspase-1 activation (p20 
subunit) and IRAK4 phosphorylation in primary mouse RPE 
cells transfected with Alu RNA±d4T. 
FIG. 45 is a Northern blot of biotin-UTP-labeled Alu 
RNA-transfected primary human RPE cells. 
FIG. 46 provides LC-MS/MS spectra of AZT-triphos-
phate (AZT-TP). 
FIG. 47 provides LC-MS/MS spectra of AZU-triphos-
phate (AZT-TP 
FIG. 48 shows the chromatographic separation of Raji 
TK- cells spiked with AZT-TP with MS spectra (inset) to 
confirm identity of designated peaks. 
FIG. 49 shows the chromatographic separation of Raji 
TK- cells spiked with AZU-TP with MS spectra (inset) to 
confirm identity of designated peaks. 
FIG. 50 is a standard curve of AZT-TP standards (black 
circle). As shown, Raji TK+ samples treated with AZT 
produced AZT-TP (white triangles), whereas AZT-TP was 
not detectable in Raji TK- cells treated with AZT. 
FIG. 51 is a Western blot of Caspase-1 activation (p20 
subunit) in primary human RPE cells transfected with Alu 
RNA, with short peptide (Panxl 10), which blocks P2X7 pore 
function but not cation flux (vs. scrambled peptide: Scr-
Panxl 10). 
FIG. 52 is a Western blot of Caspase-1 activation (p20 
subunit) in primary human RPE cells transfected with Alu 
RNA, with calmidazolium (FIG. 32 provides the chemical 
structure of IC- and EC-d4T used), which blocks P2X7 
cation flux but not pore function. 
FIG. 53 is a Western blot of Caspase-1 activation (p20 
subunit) in primary human RPE cells transfected with Alu 
RNA, with cell permeable (IC), cell-impermeable (EC), or 
unmodified (no tag) d4T. 
25 context in which the reference is made. 
30 
All combinations of method or process steps as used 
herein can be performed in any order, unless otherwise 
specified or clearly implied to the contrary by the context in 
which the referenced combination is made. 
While the following terms used herein are believed to be 
well understood by one of ordinary skill in the art, defini-
tions are set forth to facilitate explanation of the presently-
disclosed subject matter. 
Unless defined otherwise, all technical and scientific 
35 terms used herein have the same meaning as commonly 
understood by one of ordinary skill in the art to which the 
presently-disclosed subject matter belongs. Although any 
methods, devices, and materials similar or equivalent to 
those described herein can be used in the practice or testing 
40 of the presently-disclosed subject matter, representative 
methods, devices, and materials are now described. 
Following long-standing patent law convention, the terms 
"a", "an", and "the" refer to "one or more" when used in this 
application, including the claims. Thus, for example, refer-
45 ence to "a fluorophore" includes a plurality of such images, 
and so forth. 
Unless otherwise indicated, all numbers expressing quan-
tities, properties, and so forth used in the specification and 
claims are to be understood as being modified in all 
50 instances by the term "about". Accordingly, unless indicated 
to the contrary, the numerical parameters set forth in this 
specification and claims are approximations that can vary 
depending upon the desired properties sought to be obtained 
by the presently-disclosed subject matter. 
FIG. 54 shows that d4T prevents pAlu-induced mitochon- 55 
drial ROS generation in primary human RPE cells. In FIG. 
54, mitochondrial reactive oxygen species (ROS) were visu-
alized with MitoSox (Red) and cell nuclei with Hoechst 
(Blue). 
As used herein, the term "about," when referring to a 
value or to an amount of mass, weight, time, volume, 
concentration or percentage is meant to encompass varia-
tions of in some embodiments ±50%, in some embodiments 
±40%, in some embodiments ±30%, in some embodiments 
DESCRIPTION OF EXEMPLARY 
EMBODIMENTS 
60 ±20%, in some embodiments ±10%, in some embodiments 
±5%, in some embodiments ±1 %, in some embodiments 
±0.5%, and in some embodiments ±0.1 % from the specified 
amount, as such variations are appropriate to perform the 
disclosed method. The details of one or more embodiments of the presently-
disclosed subject matter are set forth in this document. 65 
Modifications to embodiments described in this document, 
and other embodiments, will be evident to those of ordinary 
As used herein, ranges can be expressed as from "about" 
one particular value, and/or to "about" another particular 
value. It is also understood that there are a number of values 
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disclosed herein, and that each value is also herein disclosed 
as "about" that particular value in addition to the value itself. 
For example, if the value "10" is disclosed, then "about 10" 
is also disclosed. It is also understood that each unit between 
10 
of the patient; the time of administration; the route of 
administration; the rate of excretion of the specific com-
pound employed; the duration of the treatment; drugs used 
two particular units are also disclosed. For example, if 10 5 
and 15 are disclosed, then 11, 12, 13, and 14 are also 
disclosed. 
in combination or coincidental with the specific compound 
employed and like factors well known in the medical arts. 
For example, it is well within the skill of the art to start doses 
of a compound at levels lower than those required to achieve 
the desired therapeutic effect and to gradually increase the 
dosage until the desired effect is achieved. If desired, the 
The term "physiologically functional derivative" means 
any pharmaceutically acceptable derivative of a compound 
of the present disclosure. For example, an amide or ester of 
a compound of formula (I) or of a compound of formula (II), 
which upon administration to a subject, particularly a mam-
mal, is capable of providing, either directly or indirectly, a 
compound of the present disclosure of an active metabolite 
thereof. 
The terms "treatment" or "treating" refer to the medical 
management of a subject with the intent to cure, ameliorate, 
stabilize, or prevent a condition or disorder ( e.g., retinal 
degradation). This term includes active treatment, that is, 
treatment directed specifically toward the improvement of a 
condition, and also includes causal treatment, that is, treat-
ment directed toward removal of the cause of the associated 
condition. In addition, this term includes palliative treat-
ment, that is, treatment designed for the relief of symptoms 
rather than the curing of the condition; preventative treat-
ment, that is, treatment directed to minimizing or partially or 
completely inhibiting the development of symptoms or 
disorders of the associated condition; and supportive treat-
ment, that is, treatment employed to supplement another 
specific therapy directed toward the improvement of the 
associated disease, pathological condition, or disorder. 
With regard to administering the compound, the term 
"administering" refers to any method of providing a com-
position and/or pharmaceutical composition thereof to a 
subject. Such methods are well known to those skilled in the 
10 effective daily dose can be divided into multiple doses for 
purposes of administration. Consequently, single dose com-
positions can contain such amounts or submultiples thereof 
to make up the daily dose. The dosage can be adjusted by the 
individual physician in the event of any contraindications. 
15 Dosage can vary, and can be administered in one or more 
dose administrations daily, for one or several days. Guidance 
can be found in the literature for appropriate dosages for 
given classes of pharmaceutical products. In further various 
aspects, a preparation can be administered in a "prophylac-
20 tically effective amount"; that is, an amount effective for 
prevention of a disease or condition. 
The terms "subject" or "subject in need thereof' refer to 
a target of administration, which optionally displays symp-
toms related to a particular disease, condition, disorder, or 
25 the like. The subject(s) of the herein disclosed methods can 
be human or non-human (e.g., primate, horse, pig, rabbit, 
dog, sheep, goat, cow, cat, guinea pig, rodent, and non-
mammals). The term "subject" does not denote a particular 
age or sex. Thus, adult and newborn subjects, as well as 
30 fetuses, whether male or female, are intended to be covered. 
The term "subject" includes human and veterinary subjects. 
As will be recognized by one of ordinary skill in the art, 
the terms "suppression," "suppressing," "suppressor," "inhi-
bition," "inhibiting" or "inhibitor" do not refer to a complete 
35 elimination of angiogenesis in all cases. Rather, the skilled 
artisan will understand that the term "suppressing" or 
"inhibiting" refers to a reduction or decrease in angiogen-
esis. Such reduction or decrease can be determined relative 
art and include, but are not limited to, oral administration, 
transdermal administration, administration by inhalation, 
nasal administration, topical administration, intravaginal 
administration, ophthalmic administration, intraaural 
administration, intracerebral administration, rectal adminis- 40 
tration, and parenteral administration, including injectable 
such as intravenous administration, intra-arterial adminis-
tration, intramuscular administration, subcutaneous admin-
istration, intravitreous administration, including via intrav-
itreous sustained drug delivery device, intracameral (into 45 
anterior chamber) administration, suprachoroidal injection, 
subretinal administration, Subconjunctival injection, sub-
Tenon's administration, peribulbar administration, Transs-
cleral drug delivery, administration via topical eye drops, 
and the like. Administration can be continuous or intermit- 50 
to a control. In some embodiments, the reduction or decrease 
relative to a control can be about a 1, 2, 3, 4, 5, 6, 7, 8, 9, 
10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 
26, 27,28,29,30, 31,32,33,34, 35,36,37,38, 39,40,41, 
42, 43,44,45,46, 47,48,49, 50, 51, 52, 53, 54, 55, 56, 57, 
58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 
74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 
90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% decrease. 
In some exemplary embodiments, the presently-disclosed 
subject matter includes methods for treating retinal damage 
and/or retinal degeneration. Indeed, some methods of the 
present disclosure comprise administering to a subject in 
need thereof an effective amount of a composition for tent. In various aspects, a preparation can be administered 
therapeutically; that is, administered to treat an existing 
disease or condition (e.g., exposure to OP compounds). In 
further various aspects, a preparation can be administered 
prophylactically; that is, administered for prevention of a 
disease or condition. 
The term "effective amount" refers to an amount that is 
sufficient to achieve the desired result or to have an effect on 
an undesired condition. For example, a "therapeutically 
effective amount" refers to an amount that is sufficient to 
achieve the desired therapeutic result or to have an effect on 
undesired symptoms, but is generally insufficient to cause 
adverse side effects. The specific therapeutically effective 
dose level for any particular patient will depend upon a 
variety of factors including the disorder being treated and 
the severity of the disorder; the specific composition 
employed; the age, body weight, general health, sex and diet 
treating retinal damage and/or degradation. 
In some embodiments the composition comprises a 
nucleoside and/or a nucleoside reverse transcriptase inhibi-
55 tor (NRTI). Further, in some embodiments, the composition 
is a pharmaceutical composition comprising a nucleoside 
and/or a NRTI compound as well as a pharmaceutically 
acceptable carrier. 
As discussed herein, in some exemplary methods of the 
60 present disclosure, the administered composition is a com-
position comprising a nucleoside and/or NRTI. Thus, exem-
plary compositions are comprised of compounds including, 
but not limited to, stavudine (d4T), lamivudine (3TC), 
cordycepin, azidothymidine (AZT), abacavir (ABC), chemi-
65 cal derivatives thereof methoxy-derivatives to abrogate 
phosphorylation), and the like. Other possible compounds 
include, for example, those described in U.S. Pat. No. 
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6,514,979 to Heredia et al. Those of ordinary skill in the art 
will also recognize further nucleosides and/or NRTis, as 
described herein, that can be used in the compositions and 
methods of this disclosure. 
12 
As described herein, the presently-disclosed subject mat-
ter further includes pharmaceutical compositions compris-
ing the compounds described herein together with a phar-
maceutically acceptable carrier. 
The term "pharmaceutically acceptable carrier" refers to 
sterile aqueous or nonaqueous solutions, dispersions, sus-
pensions or emulsions, as well as sterile powders for recon-
stitution into sterile injectable solutions or dispersions just 
prior to use. Proper fluidity can be maintained, for example, 
In some embodiments a method of the present disclosure 5 
comprises inhibiting activation of one or more physiological 
processes by Alu RNA. As disclosed herein, Alu RNA 
(including Alu repeat RNA in human cells and Bl and B2, 
Alu-like element repeat RN As) increases are associated with 
cells that are associated with certain conditions of interest. 
For example, an Alu RNA increase is associated with the 
retinal pigment epithelium (RPE) cells of eyes with geo-
graphic atrophy. This increase of Alu RNA induces the death 
10 by the use of coating materials such as lecithin, by the 
maintenance of the required particle size in the case of 
dispersions and by the use of surfactants. These composi-
tions can also contain adjuvants such as preservatives, 
wetting agents, emulsifying agents and dispersing agents. 
of RPE cells. Methods and compositions disclosed herein 
can treat RPE degradation, thereby treating conditions asso-
ciated with such cell death. 
15 Prevention of the action of microorganisms can be ensured 
by the inclusion of various antibacterial and antifungal 
agents such as paraben, chlorobutanol, phenol, sorbic acid 
and the like. It can also be desirable to include isotonic In some embodiments, a method of the present disclosure 
comprises inhibiting the activation of at least one inflam-
masome. In certain embodiments, the at least one inflam- 20 
masome is selected from an NLRP3 inflammasome, a 
IL-1 beta inflammasome, and a combination thereof. In some 
embodiments, the inhibiting one or more inflammasomes of 
a cell includes administering an inhibitor ( composition) to 
the cell and/or to a subject, wherein the cell is the cell of a 25 
subject. For compositions comprising an inhibitor, an inhibi-
tor as described herein can be, for example, a polypeptide 
inhibitor (including an oligonucleotide inhibitor), a small 
molecule inhibitor, and/or an siRNA inhibitor. 
Moreover, some exemplary methods of administering the 30 
present composition(s) can inhibit inflammation by LPS/ 
ATP, inflammasome activation by LPS/ATP, inflammasome 
activation by Alu RNA, and/or nigericin-induced inflamma-
some activation. Exemplary methods can also treat retinal 
degradation and/or other retinal damage by reducing mito- 35 
chondrial reactive oxygen species, particularly as caused by 
Alu RNA expression, by blocking entry via the P2X7 
receptor, and/or by reducing ATP-induced cell permeability. 
In some embodiments, a method of the present disclosure 
comprises treating retinal damage by inhibiting a particular 40 
action in a cell. In some embodiments, the cell is selected 
from an RPE cell, a retinal photoreceptor cell, or a choroidal 
cell. In some embodiments, the cell is an RPE cell. In some 
embodiments, the cell is the cell of a subject. In some 
embodiments, the cell is a cell of a subject having, suspected 45 
of having, or at risk of having a condition of interest. In some 
embodiments, the cell is a cell of a subject having, suspected 
of having, or at risk of having age-related macular degen-
eration. In some embodiments, the cell is a cell of a subject 
having, suspected of having, or at risk of having geographic 50 
atrophy. In some embodiments, the cell is a cell of a subject 
having, suspected of having, or at risk of having geographic 
atrophy and the cell is an RPE cell. In some embodiments, 
a subject having age-related macular degeneration can be 
treated using methods and compositions as disclosed herein. 55 
Thus, as used herein with reference to a polypeptide being 
inhibited, "of a cell" refers to a polypeptide that is inside the 
cell (inside the cell membrane), on the cell (in the cell 
membrane, presented on the cell membrane, otherwise on 
the cell), or outside of a cell, but insofar as the polypeptide 60 
is outside of the cell, it is in the extracellular milieu such that 
one of ordinary skill in the art would recognize the poly-
peptide as being associated with the cell. For example, 
VD A Cl, VDAC2, caspase-8, NFKB, or a polypeptide of an 
inflammasome (e.g., NLRP3, PYCARD, caspase-1) could 65 
be in the cell. For another example, NLRP3 could be in the 
cell or on the cell. 
agents such as sugars, sodium chloride and the like. Pro-
longed absorption of the injectable pharmaceutical form can 
be brought about by the inclusion of agents, such as alumi-
num monostearate and gelatin, which delay absorption. 
Injectable depot forms are made by forming microencapsule 
matrices of the drug in biodegradable polymers such as 
polylactide-polyglycolide, poly(orthoesters) and poly(anhy-
drides). Depending upon the ratio of drug to polymer and the 
nature of the particular polymer employed, the rate of drug 
release can be controlled. Depot injectable formulations are 
also prepared by entrapping the drug in liposomes or micro-
emulsions which are compatible with body tissues. The 
injectable formulations can be sterilized, for example, by 
filtration through a bacterial-retaining filter or by incorpo-
rating sterilizing agents in the form of sterile solid compo-
sitions which can be dissolved or dispersed in sterile water 
or other sterile injectable media just prior to use. Suitable 
inert carriers can include sugars such as lactose. 
Suitable formulations include aqueous and non-aqueous 
sterile injection solutions that can contain antioxidants, 
buffers, bacteriostats, bactericidal antibiotics and solutes 
that render the formulation isotonic with the bodily fluids of 
the intended recipient; and aqueous and non-aqueous sterile 
suspensions, which can include suspending agents and 
thickening agents. 
The compositions can take such forms as suspensions, 
solutions or emulsions in oily or aqueous vehicles, and can 
contain formulatory agents such as suspending, stabilizing 
and/or dispersing agents. Alternatively, the active ingredient 
can be in powder form for constitution with a suitable 
vehicle, e.g., sterile pyrogen-free water, before use. 
The formulations can be presented in unit-dose or multi-
dose containers, for example sealed ampoules and vials, and 
can be stored in a frozen or freeze-dried (lyophilized) 
condition requiring only the addition of sterile liquid carrier 
immediately prior to use. 
For oral administration, the compositions can take the 
form of, for example, tablets or capsules prepared by a 
conventional technique with pharmaceutically acceptable 
excipients such as binding agents ( e.g., pregelatinized maize 
starch, polyvinylpyrrolidone or hydroxypropyl methylcellu-
lose ); fillers ( e.g., lactose, microcrystalline cellulose or 
calcium hydrogen phosphate); lubricants (e.g., magnesium 
stearate, talc or silica); disintegrants (e.g., potato starch or 
sodium starch glycollate); or wetting agents (e.g., sodium 
lauryl sulphate). The tablets can be coated by methods 
known in the art. 
Liquid preparations for oral administration can take the 
form of, for example, solutions, syrups or suspensions, or 
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iting toxicities associated with NRTI-triphosphate-mediated 
polymerase inhibition (Lewis et al., 2003). Accordingly, in 
some embodiments, the present disclosure is directed to 
methods for treating retinal disease by administering 
they can be presented as a dry product for constitution with 
water or other suitable vehicle before use. Such liquid 
preparations can be prepared by conventional techniques 
with pharmaceutically acceptable additives such as suspend-
ing agents ( e.g., sorbitol syrup, cellulose derivatives or 
hydrogenated edible fats); emulsifying agents (e.g. lecithin 
or acacia); non-aqueous vehicles (e.g., almond oil, oily 
esters, ethyl alcohol or fractionated vegetable oils); and 
preservatives ( e.g., methyl or propyl-p-hydroxybenzoates or 
sorbic acid). The preparations can also contain buffer salts, 
flavoring, coloring and sweetening agents as appropriate. 
Preparations for oral administration can be suitably formu-
lated to give controlled release of the active compound. For 
buccal administration the compositions can take the form of 
tablets or lozenges formulated in conventional manner. 
5 me-d4T or another phosphorylation-incompetent nucleoside 
analog to a subject in need thereof. 
Further, in certain embodiments, the present disclosure 
provides methods for treating retinal damage, comprising: 
administering an effective amount of a composition to a 
10 subject in need thereof, wherein the composition comprises 
an NRTI. In some embodiments, the NRTI is selected from 
the group consisting ofstavudine (d4T), lamivudine (3TC), 
cordycepin, azidothymidine (AZT), abacavir (ABC), or 
derivatives or combinations thereof. 
15 In some embodiments, the presently disclosed subject 
matter provides methods for protecting an RPE cell, a retinal 
photoreceptor cell, a choroidal cell, or a combination 
thereof, comprising at least the step of administering a 
composition that comprises at least one nucleoside analog or 
The compositions can be formulated as eye drops. For 
example, the pharmaceutically acceptable carrier may com-
prise saline solution or other substances used to formulate 
eye drop, optionally with other agents. Thus, eye drop 
formulations permit for topical administration directly to the 
eye of a subject. 
20 NRTI, according to the present disclosure, to a subject in 
need thereof. 
The compositions can also be formulated as a preparation 
for implantation or injection. Thus, for example, the com-
pounds can be formulated with suitable polymeric or hydro-
phobic materials (e.g., as an emulsion in an acceptable oil) 25 
or ion exchange resins, or as sparingly soluble derivatives 
(e.g., as a sparingly soluble salt). The compounds can also 
be formulated in rectal compositions, creams or lotions, or 
transdermal patches. 
The presently-disclosed subject matter further includes a 30 
kit that can include a compound or pharmaceutical compo-
sition as described herein, packaged together with a device 
useful for administration of the compound or composition. 
As will be recognized by those or ordinary skill in the art, 
the appropriate administration-aiding device will depend on 35 
the formulation of the compound or composition that is 
selected and/or the desired administration site. For example, 
if the formulation of the compound or composition is 
appropriate for injection in a subject, the device could be a 
syringe. For another example, if the desired administration 40 
site is cell culture media, the device could be a sterile 
pipette. 
Moreover, NRTis of the present disclosure are a diverse, 
widely used, inexpensive class of small molecules, with 
extensive pharmacokinetic and safety data collected over the 45 
past several decades of human use; NRTis are therefore ripe 
for drug repurposing. As such, the present disclosure pro-
vides a novel and broadly applicable basis for use of one or 
more NRTis by addressing major unmet medical needs. 
As briefly described above, age-related macular degen- 50 
eration is a disease that affects tens of millions of people 
worldwide, and there is no effective treatment for AMD 
(Ambati and Fowler, 2012). Similarly, graft-versus host 
disease is the major obstacle preventing successful tissue 
transplant (Ferrara et al., 2009); and sterile liver inflamma- 55 
tion is a major contributor to drug-induced liver injury and 
steatohepatitis, a major determinant of fibrosis and carcino-
genesis (Kubes and Mehal, 2012). Thus, some methods 
and/or compounds of the present disclosure are intended to 
treat age-related macular degeneration, graft-versus host 60 
disease, and/or sterile liver inflammation by administering, 
in some embodiments, a compound comprising at least one 
NRTI, as provided in the present disclosure. 
Since inflammasome inhibition by NRTis can be achieved 
without phosphorylation of a particular NRTI, the use of 65 
me-d4T or other phosphorylation-incompetent nucleoside 
analogs, as provided herein, should avoid therapeutic-lim-
Moreover, in some embodiments, the present disclosure is 
directed to the synthesis and/or use of one or more com-
pounds of Formula I, Formula II, Formula III, Formula IV, 
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and/or to any salt, particularly any pharmaceutically accept-
able salt, any solvate, and/or any physiological derivative 
thereof. In some embodiments, "n" of Formula IV is any 
integer, and in a particular embodiment, n is 11. 
Further, the present disclosure provides uses of a com-
pound of any of Formulas (I), (II), (III), (IV) and/or (IV), or 
any combination thereof, in the preparation or manufacture 
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Pseudomonas aeruginosa, Vibrio cholera, Legionella spp., 
Francisella spp., and Leishmania spp. a Chlamydia spp., 
cryopyrinopathies; keratitis, acne vulgaris, Crohn's disease, 
ulcerative colitis, irritable bowel syndrome, insulin resis-
5 tance, obesity, hemolytic-uremic syndrome, polyoma virus 
infection, immune complex renal disease, acute tubular 
injury, lupus nephritis, familial cold autoinflammatory syn-
drome, Muckle-Wells syndrome and neonatal onset multi-
system inflammatory disease, chronic infantile neurologic 
10 cutaneous and articular autoinflammatory diseases, renal 
ischemia-perfusion injury, glomerulonephritis, cryoglobu-
linemia, systemic vasculitides, IgA nephropathy, malaria, 
helminth parasites, septic shock, allergic asthma, hay fever, 
chronic obstructive pulmonary disease, drug-induced lung 
15 inflammation, contact dermatitis, leprosy, Burkholderia 
cenocepacia infection, respiratory syncitial virus infection, 
psoriasis, scleroderma, reactive arthritis, cystic fibrosis, 
syphilis, Sjiigren's syndrome, inflammatory joint disease, 
non-alcoholic fatty liver disease, cardiac surgery (peri-/post-
20 operative inflammation), acute and chronic organ transplant 
rejection, acute and chronic bone marrow transplant rejec-
tion, tumor angiogenesis, and/or any combination thereof. 
Moreover, in some embodiments, the present disclosure 
provides that non-canonical NRTI function, independent of 
25 chain termination, prevents P2X7-dependent blindness, 
graft-versus-host disease and/or sterile inflammation. 
Accordingly, the present disclosure is directed, in certain 
embodiments, to methods of preventing P2X7-dependent 
blindness, graft-versus-host disease and/or inflammation in 
30 a subject by administering an effective amount of at least one 
NRTI, as described herein., to subject in need thereof. 
Further, in certain embodiments, the methods and com-
positions of the present disclosure inhibit (i) inflammasome 
activation by Alu RNA associated with a cell; (ii) inflam-
35 mation by LPS/ATP, (iii) inflammasome activation by LPS/ 
ATP, (iv) nigericin-induced inflammasome activation, and/ 
or combinations thereof. And in some embodiments, the 
inflammasome is selected from the group consisting of a 
NLRP3 inflammasome and/or a IL-1 beta inflammasome. 
of a pharmaceutical composition, such as a drug and/or 
medicine, especially a composition for the treatment of 
retinal damage and/or retinal degeneration in a mammal. In 
some embodiments, the present disclosure provides a phar- 40 
maceutical composition comprising a compound of any of 
Formulas (I), (II), (III), (IV) and/or (IV), any salt, particu-
larly any pharmaceutically acceptable salt, any solvate, 
and/or any physiological derivative thereof, together with a 
pharmaceutically acceptable carrier. 
Additionally, some embodiments of the methods of the 
present disclosure may include, for example, the steps of (i) 
blocking entry via a P2X7 receptor associated with a cell; 
(ii) reducing mitochondrial reactive oxygen species caused 
by Alu RNA expression; and/or (iii) reducing ATP-induced 
45 cell permeability of a cell. And a cell contemplated in the 
present disclosure may include, for example, an RPF: cell, 
a retinal photoreceptor cell, a choroidal cell, or any combi-
nation thereof. 
In certain embodiments, the methods and compositions of 
the present disclosure inhibit graft-versus-host disease, 
chronic pain, proliferative vitreoretinopathy, glaucoma, 
rheumatoid arthritis, multiple sclerosis, bipolar disorder, 
major depressive disorder, renal fibrosis, nephritis, pulmo- 50 
nary fibrosis, Huntington's disease, osteoporosis, chronic 
lymphocytic leukemia, anxiety disorders, pulmonary tuber-
culosis, osteoporosis in post-menopausal women and frac-
ture patients, systemic lupus erythematosus, chronic inflam-
matory and neuropathic pain, autosomal dominant 55 
polycystic kidney disease, spinal cord injury, Alzheimer's 
disease, neuropathic pain, hypertension, varicose veins, type 
1 diabetes, type II diabetes, gout, autoimmune hepatitis, 
graft vascular injury, atherosclerosis, thrombosis, metabolic 
syndrome, salivary gland inflammation, traumatic brain 60 
injury, ischemic heart disease, ischemic stroke Parkinson's 
disease, melanoma, neuroblastoma, prostate, breast, skin, 
and thyroid cancers, tubular early gastric cancer, neuroen-
docrine cancer, mucoid colon cancer, colon cancer; high-
grade urothelial carcinoma, kidney clear cell carcinoma, 65 
undifferentiated ovary carcinoma, papillary intracystic 
breast carcinoma, gram negative sepsis, infectious 
Further, NRTis are mainstay therapeutics for HIV, and 
they block retrovirus replication. Alu RNA, an endogenous 
retroelement that also requires reverse transcriptase (RT) for 
its life cycle, activates the NLRP3 inflammasome to cause 
cell death of the retinal pigment epithelium in geographic 
atrophy, which is the untreatable form of age-related macu-
lar degeneration that blinds millions of individuals. More-
over, the inventors of the present disclosure have found that 
NRTis, as a class, are novel inhibitors of the NLRP3 
inflammasome. And, surprisingly, this effect is independent 
of reverse transcriptase inhibition. 
Thus, the inventors of the present disclosure have found 
that the NRTis d4T, AZT, ABC, and 3TC block Caspase 1 
activation by Alu RNA, as does 5'-methoxy-d4T, which does 
not inhibit reverse transcriptase. Further, the present inven-
tors have found that AZT is not phosphorylated in thymidine 
kinase-deficient cells but still blocks LPS/ ATP-induced 
interleukin-I beta secretion; that NRTis block P2X7-depen-
dent YOPR0-1 dye uptake in mouse models of geographic 
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22). Also, the triphosphate metabolite of di-deoxy nucleo-
side analogs caused depletion of mitochondrial DNA; and 
consistent with the idea that me-d4T is not phosphorylated, 
it has been found that d4T, but not me-d4T reduces mtDNA 
atrophy, graft-versus-host disease, and sterile liver inflam-
mation; and that NRTis are novel inhibitors of the NLRP3 
inflammasome independent of canonical reverse tran-
scriptase inhibition. Accordingly, NRTis are ripe for drug 
repurposing in a variety of P2X7-driven diseases. 
NRTis were first discovered to be anti-viral compounds in 
1974 (Ostertag et al., 1974), and are widely used to treat 
human immunodeficiency virus (HIV). The canonical 
mechanism of action of NRTis is via chain termination of 
DNA synthesis from a viral RNA template, thereby inter-
fering with the viral life cycle of reverse transcriptase-
dependent viruses. 
5 levels. (FIG. 23). Me-d4T also prevents Alu-induced RPE 
degeneration in mice (FIG. 24). These data indicate that d4T 
can block Caspase-1 activation and RPE degeneration inde-
pendent of reverse transcriptase inhibition. 
Further, the present inventors also tested whether NRTis 
10 blocked inflammasome activation by LPS/ATP, which is not 
known to signal via reverse transcriptase (Mariathasan et al., 
2004; Mariathasan et al., 2006; Martinon et al., 2002). It was 
found that d4T inhibited LPS/ATP-induced Caspase-1 matu-
ration in primary mouse bone marrow-derived macrophages 
Age-related macular degeneration (AMD) is a leading 
cause of blindness in the elderly worldwide (Ambati et al., 
2003; Ambati and Fowler, 2012). In the more prevalent and 
untreatable dry form of AMD, overabundance of non-coding 
Alu RNAs causes blindness by inducing cell death of the 
retinal pigment epithelium (Dridi et al., 2012; Kaneko et al., 
2011; Tarallo et al., 2012). Alu sequences are non-coding 
retrotransposons that, like HIV, rely on reverse transcriptase 20 
for their life cycle (Batzer and Deininger, 2002; Dewannieux 
15 (FIG. 38) as detected by Western blot. 
et al., 2003 ). 
Caspase-1 directly processes interleukin 1 beta (IL-1 beta) 
upon LPS/ATP stimulation; d4T also blocks secretion of 
mature IL-1 beta in these cells (FIG. 39). To determine 
whether LPS/ATP-induced inflammasome activation can be 
inhibited without RT inhibition, the present inventors uti-
lized thymidine kinase-deficient (Raji/TK-) and -expressing 
(Raji/TK+) cells (Balzarini et al., 1989). After addition of 
AZT, TK-, but not TK- cells, the present inventors produced 
AZT-triphosphate (AZT-TP), the AZT metabolite required 
Alu RNA mediates RPE cell death via activation of 
Caspase 1 and the NLRP3 inflammasome (Tarallo et al., 
2012). The present disclosure provides that a reverse tran-
scriptase inhibitor, such as stavudine (d4T; 2'3' dideoxythy-
midine; Zerit, Bristol-Myers Squibb), which is FDA-ap-
proved for the treatment of HIV, prevents Caspase 1 
cleavage to its active 20 kDa form (Hentze et al., 2003; 
Yamin et al., 1996) in primary human (FIG. 34) and mouse 
RPE cells (FIG. 44) without reducing Alu RNA levels (FIG. 
45). Further, the present disclosure shows that d4T also 
blocks phosphorylation of IRAK4, a kinase downstream of 
the MyD88 adaptor that mediates Alu-induced RPE cell 
death (Tarallo et al., 2012), in human and mouse RPE cells 
(FIG. 34 and FIG. 44). The inventors of the present disclo-
sure have also found that other NRTis, including the anti-
HIV drugs azidothymidine (AZT; 3'-azido-2',3'-dideoxythy-
midine; Retrovir, ViiV Healthcare), lamivudine (3TC; 2'3' 
dideoxycytidine; Zeflix, GlaxoSmithKline) and abacavir 
(ABC; a di-deoxyguanosine analog; Ziagen, ViiV Health-
care), also block Caspase-1 cleavage induced by Alu RNA 
(FIG. 35). 
25 for RT inhibition (FIG. 40; FIG. 46, FIG. 47, FIG. 48, FIG. 
49, FIG. 50). Even though AZT was not phosphorylated in 
TK- cells, AZT still inhibited LPS/ ATP-induced inter-
leukin-I beta maturation (FIG. 41), indicating that AZT did 
not inhibit interleukin-I beta maturation via reverse tran-
30 scriptase inhibition. 
Alu RNA (Kerur et al., 2013) and LPS/ATP (Qu et al., 
2011) activate the inflammasome via the ATP receptor 
P2X7. The present inventors therefore hypothesized that 
d4T blocks P2X7 or some P2X7-dependent pathway. First, 
35 testing was conducted to determine whether d4T acts 
upstream of P2X7 by modulating ATP levels; however, d4T 
does not block release of ATP to cell culture media induced 
by Alu RNA (FIG. 42). 
Next, testing was conducted to determine whether d4T 
40 directly antagonizes P2X7 function: upon ATP binding, 
cell-surface P2X7 forms non-selective cation channels that 
Additionally, the present disclosure provides that d4T and 
AZT prevent RPE degeneration in the Alu RNA-induced 45 
mouse model of dry AMD. (Kaneko et al., 2011; Tarallo et 
al., 2012) Moreover, it has been found that mice receiving 
daily oral administration of d4T blocked RPE degeneration 
after sub-retinal injection of a plasmid expressing Alu RNA 
(FIG. 36), as did intraperitoneal administration of AZT (FIG. 50 
37). 
In order to test whether reverse transcriptase inhibition 
was required for inflammasome blockade by d4T, a 5' 
O-methyl-modified version of d4T (5'-OCH3-d4T; me-d4T) 
was synthesized (FIG. 20; FIG. 25, FIG. 36, FIG. 27, FIG. 55 
28). Accordingly, in some embodiments, the present disclo-
sure is directed to methods for synthesizing a 5' O-methyl-
modified version of d4T as provided herein. 
Only the triphosphate version of nucleoside analogs 
inhibit reverse transcriptase; the methyl modification at the 60 
5' position prevents phosphorylation and thus formation of 
nucleoside triphosphate (Nykanen et al., 2001). Accord-
ingly, like d4T, me-d4T also blocks Caspase-1 activation in 
human RPE cells (FIG. 21). 
The present inventors have confirmed that me-d4T does 65 
not inhibit reverse transcriptase: and, in contrast to urnnodi-
fied d4T, me-d4T does not block lentivirus replication (FIG. 
mediate inflammasome activation (Kahlenberg and Dubyak, 
2004; Petrilli et al., 2007). However, d4T did not signifi-
cantly modulate P2X7 cation charmel function as monitored 
by patch clamp analysis of HEK293 stable cell lines 
expressing either the human or rat P2X7 receptor (Hum-
phreys et al., 2000). 
Finally, P2X7 activation is associated with the formation 
of a large pore that is permeable to molecules of up to -1000 
Da (Adinolfi et al., 2005; Cheewatrakoolpong et al., 2005; 
Surprenant et al., 1996). It was found that d4 T, and also AZT 
and 3TC, inhibited P2X7-dependent uptake of the fluores-
cent dye YO-PRO 1 (M. W. Da) in human P2X7-overexpress-
ing HEK293 stable cell line (FIG. 43) after addition of the 
selective P2X7 agonist bzATP. 
Consistent with the idea that NRTis block Alu-induced 
P2X7-mediated inflammasome activation via a mechanism 
involving dye uptake, Alu RNA-induced Caspase-1 activa-
tion was inhibited by a small peptide that blocks P2X7-
mediated dye uptake and LPS/ATP-induced inflarmnasome 
activation, but not cation flux (Pelegrin and Surprenant, 
2006) (FIG. 51). On the other hand, Alu-induced Caspase-1 
activation was not inhibited by calmidazolium, which selec-
tively blocks P2X7-mediated cation flux but not dye uptake 
(FIG. 52). 
Furthermore, the intracellular C-terminus of P2X7 gov-
erns P2X7-associated dye uptake, and a version of d4T that 
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is not cell permeable (Agarwal et al., 2011) does not block 
caspase-1 activation by Alu RNA (FIG. 53, FIG. 32). 
Consistent with antagonism at or downstream of P2X7, but 
upstream of mitochondrial dysfunction, d4T blocks mito-
chondrial ROS (mtROS) production, which are produced 5 
upon LPS/ATP stimulation (Adinolfi et al., 2005; Cruz et al., 
2007; Garcia-Marcos et al., 2005; Nakahira et al., 2011) and 
Alu overexpression (Tarallo et al., 2012) was measured by 
MitoSOx assay (FIG. 54). Finally, d4T does not prevent 
P2X7-independent interleukin I-beta secretion in PMA- 10 
primed THP-1 cells treated with crystalline monosodium 
urate (FIG. 11) (Martinon et al., 2006; Riteau et al., 2012). 
To explore the potential therapeutic relevance of NRTis 
beyond the Alu-induced model of geographic atrophy (GA), 
it was hypothesized that if NRTis function as generic 15 
inflammasome inhibitors, then they might be broadly useful 
20 
enforced expression plasmid for Alu RNA (pAluA) for 
denoted amounts of time exhibited profoundly reduced 
viability compared to a null plasmid (pUC19), as monitored 
by MTS proliferation assay, and that d4T co-administration 
prevented cell death induced by Alu overexpression. 
In some exemplary embodiments, d4T does not rescue 
cytotoxicity via reduction in Alu RNA levels. As presented 
in FIG. 3, primary human RPE cells treated with antisense 
oligonucleotides targeting DICER! (Der as) (lane 3 (third 
lane from left)) show increased Alu RNA levels in the 
nuclear compartment compared to control antisense oligo-
nucleotides (Ctr as) (lane 1 (leftmost)), monitored by North-
ern blotting using an Alu-specific probe. Meanwhile, co-
administration of d4T (lanes 2 and 4) does not reduce Alu 
RNA levels. FIG. 3 shows u6 (bottom row) as a loading 
control for nuclear fraction. 
Moreover, in some embodiments, d4T does not reduce 
Alu RNA levels. For example, primary human RPE cells 
in other animal models of disease that are also driven by 
P2X7. In the NLRP3 inflammasome- and P2X7-driven 
graft-versus-host disease model (Jankovic et al., 2013; Wil-
helm et al., 2010), treatment of mice receiving allogeneic 
bone marrow and T cells with d4T showed improved sur-
vival compared to saline treated controls (30-70% vs. 0%). 
Furthermore, in the NLRP3- and P2X7-driven model of 
sterile inflammation (McDonald et al., 2010), d4T reduced 
neutrophil migration to the focus of liver injury. 
20 may be transfected with Alu RNA, with or without d4T. 
(FIG. 4) And, as presented in FIG. 4, co-administration of 
d4T does not change Alu RNA levels at 1, 4, or 24 hours 
after transfection in the nuclear fraction, as detected by 
Northern blotting using an Alu-specific probe. U6 (bottom 
25 row) is shown as loading control for nuclear fraction in FIG. 
4. Interestingly, it has been shown that P2X7-dependent 
pore function alone can influence phenotype (Sorge et al., 
2012). However, at present, there are not any FDA-approved 
drugs that selectively target downstream P2X7 signaling and 
not ion channel activation. Therefore, NRTis could be 30 
valuable both clinically and experimentally in the selective 
targeting of P2X7 function. 
A role for P2X7 in regulating HIV replication was 
recently proposed (Hazleton et al., 2012), and HIV patients 
have increased plasma IL-18 levels (Ahmad et al., 2002; 35 
Iannello et al., 2010), which decrease after treatment with 
NRTI-containing highly active anti-retroviral therapy (Styl-
ianou et al., 2003). Notably, reduction of plasma IL-18 levels 
by NRTI treatment of HIV-1 infected patients did not 
significantly associate with viral load or CD4+ T-cell counts 40 
(David et al., 2000), indicating that NRTis can dampen 
IL-18 levels before inhibition of viral replication occurs. 
IL-18 maturation requires pro-IL18 cleavage by active 
Caspase 1, which typically also requires P2X7 activation. 
Thus, the methods and experiments of the present disclosure 45 
are consistent with the idea that NRTis can modulate HIV-
induced cytokine expression independent of reverse tran-
scriptase inhibition. 
The present disclosure further provides that, in some 
embodiments, d4T inhibits inflanmiasome activation by Alu 
RNA. Indeed, Alu RNA causes NLRP3 inflammasome acti-
vation, which is marked by processing of the enzyme 
Caspase 1, and FIG. 5 provides a Western blot showing that 
Alu RNA causes Caspase-1 maturation in primary human 
RPE cells at 24 hours after Alu administration (Top, Lane 2, 
lower band), which is blocked by co-treatment with d4T 
(100 uM; Lane 3). The bottom row in FIG. 5 is a vinculin 
loading control. 
In certain embodiments, 3TC inhibits inflanmiasome acti-
vation by Alu RNA. Indeed, Alu RNA causes NLRP3 
inflammasome activation, which is marked by processing of 
the enzyme Caspase 1. FIG. 6 is a Western blot showing that 
Alu RNA causes Caspase-1 maturation in primary human 
RPE cells at 24 hours after Alu administration (top, lane 2, 
lower band), which is blocked with co-treatment with 3TC 
(20-100 uM; lane 3). On the bottom, the loading control, 
vinculin, is visible. 
Next, FIG. 7 provides evidence of AZT, cordycepin, and 
abacavir inhibition of inflammasome activation by Alu 
RNA. Indeed, Alu RNA causes NLRP3 inflammasome acti-
vation, which is marked by processing of the enzyme In some embodiments, d4T prevents RPE degeneration 
induced by Alu RNA in wild type mice. As shown in FIG. 50 Caspase 1. FIG. 7 is a Western blot showing that Alu RNA 
causes Caspase-1 maturation in primary human RPE cells at 
24 hours after Alu administration (top, lane 2, lower band), 
which is blocked with co-treatment with azidothymidine 
(AZT), cordycepin, and abacavir (ABC) (50-100 uM; Lanes 
1, sub-retinal Alu RNA administration to mice causes RPE 
degeneration in a mouse model of age-related macular 
degeneration. Indeed, as shown, d4T co-delivered to the 
vitreous humor of wild type mice prevents Alu RNA-
induced RPE cell death in a dose-dependent manner at one 
week after delivery. The top row of FIG. 1 provides an 
ocular fundus photograph of mice receiving control PBS, or 
Alu RNA treatment, with or without increasing amounts of 
d4T (left to right). Arrows denote depigmented regions of 
RPE cell death, which resolve at highest dose of d4T. The 60 
bottom row of FIG. 1 shows an RPE flat mount, stained for 
intercellular junctions (ZO-1) in red that are disrupted upon 
Alu RNA administration, but restored to healthy RPE mor-
phology/intercellular junctions at highest dose of d4T. 
55 3-8). Again, the loading control vinculin is shown on the 
bottom. 
Meanwhile, in certain embodiments, d4T protects against 65 
cytotoxicity induced by plasmid expressing Alu RNA in 
vitro. FIG. 2 shows that human (HeLa) cells treated with an 
In certain embodiments, the present disclosure provides 
that d4T inhibits inflanmiasome activation by LPS/ATP. As 
such, FIG. 8 provides a gel showing that primary human 
RPE cells treated with LPS/ ATP, a classic inflanmiasome 
activator, exhibit increased Casp-1 activation, and phospho-
rylation ofIRAK4, which is also a marker of inflanmiasome 
signaling via the cell surface receptor adaptor protein 
MyD88. Moreover, as shown in FIG. 8, d4T (25/100 uM) 
blocks Casp-1 activation and IRAK4 phosphorylation 
induced by LPS/ATP. The loading control in FIG. 8 is 
vinculin. Furthermore, as shown, LPS and ATP activate the 
US 10,864,212 B2 
21 
NLRP3 inflammasome only in combination, thus treatment 
with one or the other alone is useful as a control for this 
experiment. 
The present disclosure further provides that, in exemplary 
embodiments, d4T and other NRTis reduce inflammasome 5 
activation by LPS/ATP. As presented in FIG. 9, d4T, 3TC, 
and cordycepin ( at 100 uM), all di-deoxy nucleoside reverse 
transcriptase inhibitors, inhibit Caspase-1 activation ( active 
p20 band, top) and IL-18 maturation (bottom) induced by 
LPS/ATP. To produce FIG. 9, cell culture supernatants were 10 
collected after (i) no treatment, (ii) LPS treatment, or (iii) 
LPS/ATP treatment of mouse bone marrow-derived macro-
phages and run on Western blotting probing with antibodies 
for Caspase-1 and IL-18. 
In some embodiments of the present disclosure, d4T 15 
inhibits nigericin-induced inflammasome activation. Per 
FIG. 10, d4T (100, 250 uM) inhibits IL-1 beta maturation 
(top, 18 and 22 kDa forms) and Caspase-1 activation (active 
p20 band, bottom) induced by nigericin. Cell culture super-
natants were collected after (i) no treatment, (ii) LPS treat- 20 
ment, or (iii) LPS/nigericin treatment of mouse bone mar-
row-derived macrophages, and run on Western blotting 
probing with antibodies for IL-1 beta and Caspase-1. FIG. 
10 shows the results of these efforts. 
Additionally, in some embodiments, d4T does not inhibit 25 
IL-1 beta secretion from PMA-differentiated THP-1 mono-
22 
d4T. After 15 hours cells were co-stained for mtROS (red) 
and for cell count, nuclei (blue; Hoechst DNA stain). Cells 
in the pAluA group exhibited greater mtROS staining (red) 
compared to pUC19 control, an effect that is reduced in 
pAluA+d4T treated cells. 
And in further embodiments, d4T does not inhibit ATP 
release induced by Alu RNA. (FIG. 16) Primary human RPE 
cells treated with Alu RNA for the times indicated release 
ATP. To provide FIG. 16, cell culture supernatant was 
collected from mock or Alu RNA treated cells, with or 
without d4T. ATP was detected using an ATP-dependent 
luciferase assay. And, notably, d4T did not affect ATP 
release. 
In certain embodiments, d4T reduces ATP-induced cell 
permeability to Yo-Prol (P2X7 receptor assay), as shown in 
FIG. 17. To prepare FIG. 17, THP-1 cells differentiated into 
macrophages by PMA allowed entry of the large fluorescent 
dye Yo-Pro 1, in an assay for P2X7 receptor activity. It was 
observed that d4T dose-dependently reduced Yo-Pro entry 
induced by ATP, determined by an area-scan fluorescent 
measurement in a 96 well microplate reader. Indeed, FIG. 17 
provides the results of the fluorescence measurement in 
relative fluorescence units (RFU, y-axis). 
Furthermore, it has been shown that d4T reduces extra-
cellular potassium levels that increase after Alu RNA trans-
fection. (FIG. 18) Indeed, cell culture potassium levels 
increase in primary human RPE cells treated with Alu RNA 
for 6 hours, an effect that is reduced by d4T co-administra-
cytes induced by MSU. Human THP-1 monocytes were 
differentiated into macrophages with PMA. As shown in 
FIG. 11, treatment with monosodium urate (MSU), a known 
inflammasome activator, increased IL-1 beta secretion com-
pared to non-treated cells, whereas d4T co-administration at 
a range of doses (25-1000 uM) did not significantly affect 
IL-1 beta secretion. Further, d4 T does not block MSU-
induced IL-1 beta secretion as determined by ELISA (n=3-
4). 
30 tion. For FIG. 18, potassium levels were determined in cell 
culture supernatants spectrophotometrically using a potas-
sium-dependent pyruvate kinase assay. 
In certain embodiments, d4T and other nucleoside reverse 
transcriptase inhibitors do not inhibit IL-1 beta secretion 
from PMA-differentiated THP-1 monocytes induced by 
MSU. To illustrate this, human THP-1 monocytes were 
differentiated into macrophages with PMA. Treatment with 
MSU increased IL-1 beta secretion compared to non-treated 
cells. (FIG. 12) Meanwhile d4T, 3TC, or cordycepin (all are 
di-deoxy nucleotide analogs) co-administration at a range of 
doses (25-1000 uM) did not significantly affect IL-1 beta 
secretion, as shown in FIG. 12. 
Next, in some embodiments, d4T reduces NLRP3 priming 
induced by Alu RNA. Indeed, as provided in the bar graph 
Next, in some embodiments, d4T blocks bzATP-induced 
35 
cell permeability to Yo-Prol (P2X7 receptor assay), as 
shown in FIG. 19. d4T blocked YO-PRO-1 iodide entry in 
HEK293 cells stably expressing the human P2X7 receptor 
stimulated with the P2X7-selective agonist bzATP. Cells 
were pre-incubated with d4T for 30 minutes prior to addition 
40 of bzATP/YO-PRO, and fluorescence at 485/515 nm mea-
45 
sured at t=30 minutes. 
Moreover, d4T blocks Alu-induced RPE degeneration and 
Caspase-1 activation independent of reverse transcriptase 
inhibition. 
In some embodiments, the present disclosure is directed 
to a compound having the structure(s) provided in FIG. 20. 
of FIG. 13, Alu RNA transfection increases NLRP3 mRNA 
levels in primary human RPE cells at 16 hours, an event 
termed "priming" (Y-axis) compared to mock (transfection 50 
reagent alone). This effect is blunted by co-administration of 
d4T (100 uM) and normalized to 18S RNA control. 
FIG. 20 includes a chemical structure of methoxy-d4T 
(me-d4T) and of d4T. As shown in FIG. 20, a single 
substitution of the ribose 5' hydroxyl group with a methoxy 
group ( circled) has been designed by the inventors of the 
present disclosure to prevent d4T phosphorylation. Accord-
ingly, in some embodiments, the present disclosure is 
directed to a compound comprising a single substitution of 
a ribose 5' hydroxyl group with a methoxy group. And, in 
some embodiments, the present disclosure provides com-
pounds comprising a methoxy group in place of a ribose 5' 
Furthermore, in exemplary embodiments of the present 
disclosure, d4 T reduces IL-1 beta priming induced by Alu 
RNA. FIG. 14 illustrates that Alu RNA transfection 55 
increases IL-1 beta mRNA levels in primary human RPE 
cells at 24 hours, an event termed "priming", (Y-axis) 
compared to mock (transfection reagent alone). This effect is 
blunted by co-administration of d4T (100 uM) and normal-
ized to 18S RNA control. 
Meanwhile, in some embodiments, d4T reduces mito-
chondrial ROS caused by Alu expression. FIG. 15 demon-
strates that enforced expression of Alu (pAluA) causes 
increased mitochondrial reactive oxygen species (mtROS), 
as detected by MitoSox assay. In order to produce FIG. 15, 
primary human RPE cells were incubated with Alu express-
ing plasmid or control plasmid (pUC19) with or without 
hydroxyl group for preventing phosphorylation, such as d4T 
phosphorylation. 
The present disclosure further provides the results of 
60 additional experiments in FIG. 21-FIG. 23. Indeed, FIG. 21 
is a Western blot of Caspase-1 activation (p20 subunit) in 
primary human RPE cells transfected with Alu RNA±me-
d4T; FIG. 22 shows cells, wherein unmodified d4T, but not 
me-d4 T, blocks replication of a GFP-expressing lentivirus in 
65 HeLa cells; and FIG. 23 provides a graph illustrating that 
unmodified d4T, but not me-d4T, reduces mtDNA levels 
(normalized to chromosomal DNA exon-intron junction 
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sequence) in primary mouse RPE cells as determined by 
real-time quantitative PCR. n=4, *p<0.05 by Student's 
t-test. 
In some embodiments, it has been shown that Me-d4T 
(intraperitoneal injection) prevents Alu-induced RPE degen- 5 
eration in mice. FIG. 24, top row, provides flat mounts 
stained for zonula occludens-1 (ZO-1; red), bottom row. 
Degeneration is outlined if FIG. 24 by blue arrowheads. 
Representative images of n=4 are shown. 
Meanwhile, FIG. 25 provides a schematic overview of 10 
me-d4T synthesis, and FIG. 26 is an HPLC chromatogram 
of me-d4T (peak #6) final product, >97% purity. And FIG. 
27 is a lH NMR spectroscopy of me-d4T final product, 
wherein the chemical shifts are consistent with the structure, 
and FIG. 28 provides the results of liquid chromatography/ 15 
mass spectrometry of me-d4T final product, m/z ratio con-
sistent with the structure. 
FIG. 29, FIG. 30 and FIG. 31 provide for methoxy 
variants of nucleoside analogs. Specifically, FIG. 29 shows 
the chemical structure of 3TC (2'3' dideoxycytidine); FIG. 20 
30 provides the chemical structure of AZT (3'-azido-2',3'-
dideoxythymidine); and FIG. 31 shows the chemical struc-
ture of ABC ( cyclopropylaminopurinylcyclopentene ). In 
each of FIGS. 29-31, the methoxy variation (O-methyl 
group) of nucleoside analog is circled. Further, FIG. 32 25 
shows a cell permeant variant of d4T (IC-d4T), where "n" 
group is equal to 11. Derivatives include cell permeant 
variants of 3TC, AZT, ABC, where the nucleobase group 
( circled) may be replaced, in various embodiments, by 3 TC, 
AZT, ABC, or methoxy-variants of d4T, 3TC, AZT, ABC 30 
(FIG. 29-31), or derivatives thereof. 
Meanwhile, FIG. 33 provides the chemical structure of an 
exemplary NRTI according to the present disclosure. 
In certain embodiments, the present disclosure provides 
that NRTis block Alu-induced RPE degeneration and/or 35 
Caspase-1 activation. For example, FIG. 34 shows a Western 
blot of Caspase-1 activation (p20 subunit) and IRAK4 
phosphorylation in primary human RPE cells transfected 
with Alu RNA±d4T. FIG. 35 is a Western blot ofCaspase-1 
activation in human RPE cells transfected with Alu 40 
RNA±NRTis (3TC, AZT, ABC). FIG. 36 shows that pAlu 
causes RPE degeneration, which is prevented by oral admin-
istration of d4T, and FIG. 37 shows that pAlu causes RPE 
degeneration, which is prevented by intraperitoneal admin-
istration of AZT. FIG. 36 and FIG. 37 include fundus 45 
photographs: top row; flat mounts stained for zonula 
occludens-1 (ZO-1; red), bottom row. Degeneration is out-
lined by blue arrowheads. Scale bars, 50 µm. 
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from primary human RPE cells (n=4). Meanwhile, FIG. 43 
is a graph illustration showing that NRTis selectively block 
P2X7 pore function and P2X7-driven models of graft rejec-
tion and sterile liver inflammation, providing a graph of the 
fluorescence (% of bzATP) over time (minutes). 
And in certain exemplary embodiments, the present dis-
closure provides that d4T blocks Caspase-1 activation with-
out reducing Alu RNA levels. Accordingly, FIG. 44 provides 
a 
Western blot of Caspase-1 activation (p20 subunit) and 
IRAK4 phosphorylation in primary mouse RPE cells trans-
fected with Alu RNA±d4T. And FIG. 45 presents a Northern 
blot of biotin-DTP-labeled Alu RNA-transfected primary 
human RPE cells. Notably, in FIG. 45, d4T did not reduce 
Alu RNA levels (normalized to u6 RNA). 
Next, FIGS. 46-47 provide LC-MS/MS spectra of AZT-
triphosphate (AZT-TP, target compound; FIG. 46) andAZU-
triphosphate (AZU-TP, internal standard; FIG. 47). And 
FIGS. 48-49 show the chromatographic separation of Raji 
TK- cells spiked withAZT-TP (FIG. 48) andAZU-TP (FIG. 
49) with MS spectra (insets) to confirm identity of desig-
nated peaks. 
FIG. 50 is a standard curve of AZT-TP standards (black 
circle). Raji TK+ samples treated with AZT producedAZT-
TP (white triangles), whereas AZT-TP was not detectable in 
Raji TK- cells treated with AZT. FIG. 50 is representative of 
two experiments. 
FIGS. 51-54 show that, in some exemplary embodiments, 
P2X7-dependent pore function mediates Alu-induced 
Caspase-1 activation. Indeed, FIG. 51 is a Western blot of 
Caspase-1 activation (p20 subunit) in primary human RPE 
cells transfected with Alu RNA, with short peptide 
(Panxl 10), which blocks P2X7 pore function but not cation 
flux (vs. scrambled peptide: Ser Panxl 10); FIG. 52 is a 
Western blot of Caspase-1 activation (p20 subunit) in pri-
mary human RPE cells transfected with Alu RNA, with 
calmidazolium (FIG. 32 provides the chemical structure of 
IC- and EC-d4T used), which blocks P2X7 cation flux but 
not pore function; and FIG. 53 is a Western blot of 
Caspase-1 activation (p20 subunit) in primary human RPE 
cells transfected with Alu RNA, with cell permeable (IC), 
cell-impermeable (EC), or unmodified (no tag) d4T. Fur-
thermore, FIG. 54 shows that d4T prevents pAlu-induced 
mitochondrial ROS generation in primary human RPE cells. 
In FIG. 54, mitochondrial reactive oxygen species (ROS) 
were visualized with MitoSox (Red) and cell nuclei with 
Hoechst (Blue). 
One of ordinary skill in the art will recognize that addi-
tional embodiments or implementations are possible without 
50 departing from the teachings of the present disclosure or the 
scope of the claims which follow. This detailed description, 
and particularly the specific details of the exemplary 
embodiments and implementations disclosed herein, is 
given primarily for clarity of understanding, and no unnec-
FIGS. 38-41 illustrate that NRTis block LPS/ATP-in-
duced inflammasome activation. FIGS. 38 and 39 show that 
d4T blocked Caspase-1 (FIG. 38) and IL-1 beta (FIG. 39) 
activation in LPS/ ATP treated primary mouse bone marrow-
derived macrophages as determined by western blot of cell 
culture media and lysate. Moreover, FIG. 40 presents chro-
matograms showing that Raji TK- cells, but not Raji TK-
cells, phosphorylate AZT to AZT-triphosphate (AZT-TP) as 
determined by liquid chromatography-mass spectrometry 
(LC-MS). And FIG. 41 shows that AZT blocks IL-1 beta 
activation by LPS/ATP in both Raji TK- and TK+ cells as 
determined by western blot of cell lysates. Representative 60 
images ofn=3-4 experiments are provided in each of FIGS. 
38-41. 
In some embodiments, the present disclosure provides 
that NRTis selectively block P2X7 pore function and P2X7-
driven models of graft rejection and sterile liver inflamma-
tion, as shown in FIGS. 42-43. FIG. 42 is a bar graph 
illustrating that d4 T does not block Alu-induced ATP release 
55 essary limitations are to be understood therefrom, for modi-
fications will become obvious to those skilled in the art upon 
reading this disclosure and may be made without departing 
from the spirit or scope of the claimed invention. 
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(i) a compound having the structure of formula I 
(I) 
or a pharmaceutically acceptable salt thereof; 
(ii) a compound having the structure of formula II 
(II) 
US 10,864,212 B2 
29 
(iii) a compound having the structure of formula III, or a 
pharmaceutically acceptable salt thereof; 
(III) 5 
(iv) a compound having the structure of formula IV, 
HO 
wherein n is 10 to 20; 
(v) a compound having the structure of formula V 
(vi) stavudine (d4T); 
(vii) lamivudine (3TC); 
(viii) cordycepin; 
(ix) azidothymidine (AZT); 
(x) abacavir (ABC); and 
















2. The method of claim 1, wherein the compound is 
selected from: 
(i) the compound having the structure of formula I 
(I) 
or a pharmaceutically acceptable salt thereof; 




(iii) the compound having the structure of formula III, or 
a pharmaceutically acceptable salt thereof; 
(III) 
US 10,864,212 B2 
31 32 








(iii) a compound having the structure of formula V 
wherein n is 10 to 20; 20 
(v) a compound having the structure of formula V 
(V) 
0 







(vi) a combination thereof. 
3. The method of claim 1, wherein n is 11. 
4. The method of claim 1, wherein the compound is 45 
selected from: 





or a pharmaceutically acceptable salt thereof; 
(iv) a combination thereof. 
5. The method of claim 1, wherein the compound 1s 
selected from: 
(i) the compound having the structure of formula 
(I) 
or a pharmaceutically acceptable salt thereof; 
US 10,864,212 B2 
33 
(ii) a compound having the structure of formula V 
(V) 
and 
(iii) a combination thereof. 
6. The method of claim 1, wherein the compound is a 
compound having the structure of formula I 
(I) 









7. The method of claim 1, wherein the compound is the 
compound having the structure of formula II: 
(II) 
0. 
8. The method of claim 1, wherein the compound is the 
compound having the structure of formula V: 
(V) 
9. The method of claim 1, wherein the compound 1s 
selected from 
(vi) stavudine (d4T); 
(vii) lamivudine (3TC); 
(viii) cordycepin; 
(ix) azidothymidine (AZT); 
(x) abacavir (ABC); and 
(xi) a combination thereof. 
10. The method of claim 1, wherein the method comprises 
45 administering a composition comprising the compound and 
a pharmaceutically acceptable carrier. 
11. The method of claim 1, wherein the condition is 
Parkinson's disease. 
12. The method of claim 1, wherein the condition is 
50 Alzheimer's disease. 
13. The method of claim 1, wherein the condition is 
multiple sclerosis. 
* * * * * 
